Fresenius Kabi Launches Acetylcysteine 10% Solution
Fresenius Kabi announced the launch of Acetylcysteine Solution, 10%.
Acetylcysteine via inhalation is used as a mucolytic agent, as adjuvant therapy in patients with abnormal, viscid, or inspissated mucous secretions in such conditions as chronic bronchopulmonary disease, acute bronchopulmonary disease, pulmonary complications of cystic fibrosis, tracheostomy care, pulmonary complications associated with surgery, use during anesthesia, post-traumatic chest conditions, atelectasis due to mucous obstruction, and diagnostic bronchial studies.
Acetylcysteine given orally is indicated as an antidote to prevent or lessen hepatic injury following acetaminophen overdose.
Acetylcysteine Solution 10% is available in 4mL, 10mL, and 30mL vials.
For more information call (888) 386-1300 or visit Fresenius-Kabi.us.